Skip to main content

Table 2 Adjusted hazard ratios for breast cancer death by IHC subtypes, grade and pTN

From: In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study

IHC subtype Grade Patients (N)/deaths (n) pT1pN0 pT2pN0 pT1-2pN+ pT3-4pN0/+
pT1pN0 pT2pN0 pT1-2pN+ pT3-4pN0/+
N/n N/n N/n N/n HR [95% CI] HR [95% CI] HR [95% CI] HR [95% CI]
ER+PR+HER2− I 2498/17 225/7 592/22 30/2 1.0 [ref] 3.6 [1.5, 8.6] 4.2 [2.2, 7.9] 6.3 [1.5, 27.5]
II 3175/36 805/23 1892/117 149/25 1.6 [0.9, 2.8] 3.6 [1.9, 6.7] 7.3 [4.4, 12.2] 15.5 [8.3, 28.9]
III 556/25 332/24 641/83 51/16 6.4 [3.4, 11.8] 10.5 [5.6, 19.7] 16.7 [9.9, 28.2] 39.8 [20.0, 79.6]
ER+PR−HER2− I 445/2 30/1 80/5 8/0 0.7 [0.2, 2.9] 4.3 [0.6, 32.5] 7.9 [2.9, 21.5] N/A
II 650/16 173/10 377/50 37/8 3.3 [1.7, 6.6] 7.5 [3.4, 16.4] 14.3 [8.2, 24.9] 24.8 [10.6, 57.9]
III 214/11 158/16 237/46 15/3 8.5 [4.0, 18.2] 16.2 [8.2, 32.2] 24.5 [14.0, 42.9] 22.3 [6.5, 76.4]
ER+PR+HER2+/ER+PR−HER2+a II 376/6 114/5 266/21 23/2 2.1 [0.8, 5.3] 6.0 [2.2, 16.2] 8.5 [4.4, 16.1] 7.6 [1.7, 32.8]
III 286/12 149/12 344/26 14/3 5.6 [2.7, 11.7] 11.1 [5.3, 23.3] 9.3 [5.0, 17.2] 21.3 [6.2, 73.1]
HER2pos II 82/1 21/1 63/7 5/2 1.3 [0.2,9.4] 7.2 [1.0, 53.8] 12.9 [5.3, 31.2] 44.5 [10.2,193.5]
III 168/10 110/8 247/28 30/8 6.7 [3.1, 14.6] 9.2 [3.9, 21.3] 12.8 [7.0, 23.4] 27.6 [11.9, 64.4]
TNBC II 150/6 45/7 59/12 6/3 4.8 [1.9, 12.1] 17.8 [7.4, 43.1] 22.3 [10.6, 46.8] 86.9 [25.4, 297.5]
III 488/34 368/40 393/80 27/8 9.2 [5.1, 16.5] 14.4 [8.2, 25.5] 25.8 [15.2, 43.7] 28.5 [12.2, 66.5]
  1. Hazard ratios adjusted for age and year of diagnosis, subtype × grade × pTN status interaction, surgery type and follow-up. Restricted to M0. N = 17,204. Test of interaction: 3-way interaction IHC subtype × grade × pTN status vs. IHC subtype × grade + pTN status, p = 0.4333. Test of interaction: 2-way interaction IHC subtype × grade + pTN status vs. IHC subtype + grade + pTN status, p = 0.0022
  2. HER2pos ERPRHER2+, TNBC ERPRHER2
  3. aER+PR+HER2+ and ER+PRHER2+ combined into one category